GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Status:
Recruiting
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of GPED (gemcitabine,
pegaspargase, etoposide, and dexamethasone) regimen in the treatment of Relapsed/Refractory
or advanced NK/T-cell lymphoma patients